Want to take quizzes and track your credits?
With COVID-19 dominating the news, it is easy to forget that up until a year ago, the US public’s top domestic priorities for Congress were improving the affordability of health care and prescription drugs. But the need for action has only increased during the pandemic as millions of people in the US lost employer-sponsored insurance, states incurred massive expenses, and prescription drug prices continued their upward march.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Correction: This article was corrected on March 1, 2021, to add the Conflict of Interest Disclosure appearing last for Dr Mello.
Corresponding Author: Michelle M. Mello, JD, PhD, MPhil, Stanford Law School and Stanford School of Medicine, Department of Health Research and Policy, 559 Nathan Abbott Way, Stanford, CA 94305 (firstname.lastname@example.org).
Conflict of Interest Disclosures: Dr Mello reported receiving grants from Arnold Ventures for projects on policies to address prescription drug costs; receiving consulting fees from the National Academy for State Health Policy for writing reports assessing the legality of prescription drug price regulation proposals; serving as an advisor to CVS Caremark on its value-based formulary product but has not received fees from the company; and receiving personal fees from law firms for expert witness testimony in support of plaintiff drug companies and pharmacies alleging anticompetitive pricing practices. Ms Riley reported receiving grants from Arnold Ventures for projects relating to state policies for improving prescription drug affordability.
Previous Publication: This article was previously published in JAMA Health Forum at jamahealthforum.com.
You currently have no searches saved.